Tsubota Laboratory Incorporated (4890) AI Stock Analysis

• Market Cap: ¥7.87B
• Dividend Yield: N/A
• Average Volume (3M): 31.02K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.15
• Revenue Growth: -12.40%
• EPS Growth: 43.42%
• Country: JP
• Employees: 7
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Pharmaceuticals
• EPS (TTM): -7.22
• Shares Outstanding: 25,794,300
• 10 Day Avg. Volume: 26,720
• 30 Day Avg. Volume: 31,016
• PEG Ratio: -0.37
• Price to Book (P/B): 6.35
• Price to Sales (P/S): 7.43
• P/FCF Ratio: -30.40
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 68 Neutral
• Price Target: ¥334.00 ▼(-1.76% Downside)
• Action: Reiterated Date: 03/13/26
• Date: Action: Reiterated 03/13/26

The score is primarily supported by solid financial strength and improving operating performance, alongside a strong technical uptrend. These positives are tempered by persistent negative operating/free cash flow and a negative P/E, which reduce confidence in valuation and cash-generation quality.

Positive Factors

Balance sheet strength

A strong equity base and low leverage provide durable financial flexibility, lowering refinancing and solvency risk. This capital structure supports continued R&D investment and partner deals over months, making the business more resilient to revenue swings and enabling strategic execution.

Negative Factors

Negative operating and free cash flow

Persistent negative OCF and FCF erode liquidity and constrain the firm's ability to self-fund R&D or commercial expansion. Over a 2–6 month horizon, continued cash burn raises financing dependency and increases execution risk for product launches or regulatory activities.

Tsubota Laboratory Incorporated Business Overview & Revenue Model

Company Description

Tsubota Laboratory Incorporated engages in the research and development of pharmaceuticals and medical devices for the treatment of myopia, dry eyes, and presbyopia. The company was incorporated in 2012 and is based in Tokyo, Japan....

How the Company Makes Money

Tsubota Laboratory makes money primarily by commercializing its eye-health-related technologies and products. Key revenue streams include: (1) sales of company-developed products in its focus areas (including myopia-related offerings), where reven...

Read more

Tsubota Laboratory makes money primarily by commercializing its eye-health-related technologies and products. Key revenue streams include: (1) sales of company-developed products in its focus areas (including myopia-related offerings), where reven...

Tsubota Laboratory Incorporated Financial Statement Overview

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	1.36B	1.36B	673.53M	954.69M	640.92M	687.50M
Gross Profit	1.15B	1.15B	-9.48M	686.83M	528.76M	592.57M
EBITDA	219.47M	262.46M	-609.24M	206.22M	173.87M	264.71M
Net Income	178.16M	205.77M	-641.32M	90.18M	153.32M	201.61M
Balance Sheet
Total Assets	2.02B	2.50B	2.30B	2.67B	1.62B	1.08B
Cash, Cash Equivalents and Short-Term Investments	1.47B	1.54B	1.88B	2.16B	1.17B	610.77M
Total Debt	85.26M	90.38M	116.90M	139.34M	223.82M	242.35M
Total Liabilities	627.88M	915.85M	927.93M	722.59M	873.44M	487.54M
Stockholders Equity	1.39B	1.59B	1.37B	1.95B	744.35M	591.03M
Cash Flow
Free Cash Flow	0.00	-331.75M	-313.35M	-15.27M	582.69M	-940.00K
Operating Cash Flow	0.00	-317.75M	-301.35M	28.49M	654.91M	36.72M
Investing Cash Flow	0.00	-14.55M	-12.00M	-54.03M	-72.23M	-43.60M
Financing Cash Flow	0.00	-12.25M	35.74M	1.01B	-18.53M	236.97M

Tsubota Laboratory Incorporated Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 340.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4890, the sentiment is Negative. The current price of 340 is below the 20-day moving average (MA) of 342.95, above the 50-day MA of 311.08, and below the 200-day MA of 346.21, indicating a bearish trend. The MACD of -4.89 indicates Positive momentum. The RSI at 45.16 is Neutral, neither overbought nor oversold. The STOCH value of 33.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4890.

Tsubota Laboratory Incorporated Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
9989	69 Neutral	¥459.04B	14.05	11.37%	3.04%	6.32%	8.19%
4890	68 Neutral	¥7.87B	-11.77	―	―	-12.40%	43.42%
3549	67 Neutral	¥366.97B	16.82	―	0.41%	15.81%	27.05%
7649	66 Neutral	¥677.19B	23.29	15.71%	0.96%	21.81%	67.76%
3391	62 Neutral	¥1.01T	19.41	―	1.72%	―	―
3349	60 Neutral	¥524.40B	22.79	―	0.93%	3.73%	18.84%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Tsubota Laboratory Incorporated Corporate Events